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ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now
spread across the globe. As part of the worldwide response, many molecular diagnostic platforms have been granted emergency use authorization (EUA) by the Food
and Drug Administration (FDA) to identify SARS-CoV-2 positive patients. Our objective was to evaluate three sample-to-answer molecular diagnostic platforms (Cepheid Xpert Xpress SARS-CoV-2 [Xpert Xpress], Abbott ID NOW COVID-19 [ID NOW],
and GenMark ePlex SARS-CoV-2 Test [ePlex]) to determine analytical sensitivity, clinical performance, and workﬂow for the detection of SARS-CoV-2 in nasopharyngeal
swabs from 108 symptomatic patients. We found that Xpert Xpress had the lowest
limit of detection (100% detection at 100 copies/ml), followed by ePlex (100% detection at 1,000 copies/ml), and ID NOW (20,000 copies/ml). Xpert Xpress also had highest positive percent agreement (PPA) compared to our reference standard (98.3%)
followed by ePlex (91.4%) and ID NOW (87.7%). All three assays showed 100% negative percent agreement (NPA). In the workﬂow analysis, ID NOW produced the lowest time to result per specimen (⬃17 min) compared to Xpert Xpress (⬃46 min) and
ePlex (⬃1.5 h), but what ID NOW gained in rapid results, it lost in analytical and clinical performance. ePlex had the longest time to results and showed a slight improvement in PPA over ID NOW. Information about the clinical and analytical performance of these assays, as well as workﬂow, will be critical in making informed and
timely decisions on testing platforms.
KEYWORDS COVID-19, EUA, SARS-CoV-2, molecular diagnostics, nasopharyngeal,
near-patient testing

T

he outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
subsequent cases of coronavirus disease 2019 (COVID-19) (1), which began in
Wuhan, China, had spread to more than 200 countries and territories by the end of
December 2019. As of 15 April 2020, over two million cases have been conﬁrmed,
causing over ⬃133,000 deaths according to the Centers for Disease Control and
Prevention (CDC) and the database of the Center for Systems Science and Engineering
(CSSE) at Johns Hopkins University (2, 3).
SARS-CoV-2 is the seventh coronavirus known to be transmitted from human to
human, has high rates of transmission, and is also relatively stable in aerosols and on
surfaces (4–6). Infection with SARS-CoV-2 can cause mild to severe respiratory illness,
including symptoms such as fatigue, shortness of breath, cough, and fever. In addition,
some individuals experience rapidly progressive and severe disease. The elderly and
those with serious underlying medical conditions (e.g., cardiovascular disease, diabetes,
lung disease, and immunocompromised individuals) are most at risk of developing
fulminant disease (4). Currently, there are no available speciﬁc therapeutics or vaccines
approved by the FDA for treatment or prevention of COVID-19 (7). In addition, the
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SARS-CoV-2 pandemic has coincided with inﬂuenza season in many locations. These
challenges have presented a major hurdle for slowing the global spread of disease and
have necessitated the need for rapid and accurate SARS-CoV-2 diagnostic testing to
implement effective infection control measures.
Currently available molecular diagnostics platforms include several sample-toanswer platforms that have been issued an emergency use authorization (EUA) by the
FDA to qualitatively detect SARS-CoV-2 RNA in symptomatic patients. All three sampleto-answer platforms evaluated in this study are individual cartridge-based tests that are
likely to be widely utilized by hospital laboratories. In addition, both Xpert Xpress and
ID NOW are also authorized for use in patient care settings outside the clinical
laboratory environment and are therefore highly likely to be considered for patient
testing in the outpatient environment.
In this study, our objective was to evaluate the analytical and clinical performance
as well as the workﬂow of these three sample-to-answer platforms for SARS-CoV-2
detection in 108 nasopharyngeal (NP) swab specimens from symptomatic patients.
MATERIALS AND METHODS
Specimen collection and storage. Nasopharyngeal (NP) swabs were collected from symptomatic
patients. A sterile swab made from Dacron, rayon, or nylon was used for each collection. The NP swab
was then placed into sterile 3-ml universal transport medium (UTM) (various manufacturers). Samples
were then transported and tested as close to the time of collection as possible. The specimens were
stored at 2 to 8°C for up to 72 h. Following routine patient testing, samples were aliquoted and stored
at – 80°C until comparator testing could occur.
Study design. A total of 108 nasopharyngeal samples (50 negative and 58 positive specimens) tested
between March to April of 2020 were selected for this study and included samples from symptomatic
patients of all genders and ages. This work was conducted as a quality improvement activity in order to
complete each assay validation. The 108 specimens included 88 retrospective samples initially tested on
ePlex and then immediately aliquoted and frozen at – 80°C, remaining frozen until this study was
performed. Retrospective samples were thawed and immediately tested using the Hologic Panther
Fusion SARS-CoV-2 assay (reference standard) and the ID NOW and Xpert Xpress assays. The prospective
20 specimens were processed fresh on each platform at the time of patient testing. The specimens
selected represented our true positivity rate at the time that this study was performed (50 to 60%) and
also included positive specimens spanning the range of positivity levels, including those with low viral
loads (characterized by high cycle threshold [CT] values obtained by the reference method).
Cepheid Xpert Xpress SARS-CoV-2 assay. The Xpert Xpress assay is a molecular in vitro diagnostic
test utilizing widely used real-time reverse transcription PCR (RT-PCR) ampliﬁcation technology to detect
the nucleocapsid gene (N2) and the envelope gene (E) in upper respiratory specimens and is performed
on the GeneXpert instrument system. All testing was performed according to the manufacturer’s
instructions. Brieﬂy, the contents of the specimen collection tube are mixed by rapidly inverting the tube
ﬁve times and then 300 l of NP specimen is transferred to the sample chamber of the assay cartridge.
The lid is then closed and the cartridge is loaded onto the GeneXpert platform, which performs
automated sample processing and real-time RT-PCR for viral RNA detection.
Abbott ID NOW COVID-19 assay. ID NOW is a rapid molecular in vitro diagnostic test utilizing
isothermal nucleic acid ampliﬁcation technology to detect the RNA-dependent RNA polymerase (RdRp)
gene segment of SARS-CoV-2 and is performed on the ID NOW instrument. It consists of a sample
receiver containing elution/lysis buffer, a test base, and a transfer cartridge for transfer of the eluted
sample to the test base and ID NOW instrument. All testing was performed according to the manufacturer’s instructions. Brieﬂy, a test base and a sample receiver are inserted into the ID NOW instrument.
When the operator is prompted to do so via on-screen instructions, 200 l of NP specimen is added to
the sample receiver and then immediately transferred to the test base using the provided transfer
cartridge, initiating target ampliﬁcation.
GenMark ePlex SARS-CoV-2 assay. The ePlex assay is an in vitro diagnostic test that targets the N
gene of SARS-CoV-2 and uses a combination of electrowetting and GenMark’s eSensor technology for
extraction, ampliﬁcation, and detection using competitive DNA hybridization and electrochemical detection. All testing was performed according to the manufacturer’s instructions. Brieﬂy, the specimen is
initially subjected to vortex mixing, after which 200 l of NP specimen is added to the sample delivery
device (SDD) provided with the ePlex SARS-CoV-2 kit and subjected to vortex mixing for 10 s. The entire
volume of the SDD is dispensed into the sample loading port of the SARS-CoV-2 test cartridge, followed
by pushing down the cap to seal the sample delivery port. The cartridge is bar-coded and scanned with
the ePlex instrument barcode scanner and is then loaded into an available ePlex bay, which performs
extraction, ampliﬁcation, and detection.
Hologic Panther Fusion SARS-CoV-2 assay (reference standard assay). The Fusion SARS-CoV-2
assay was used as the reference standard for all three assays evaluated in this study and was performed
according to the manufacturer’s instructions for use. NP specimens are lysed by transferring 500 l of
specimen into a specimen lysis tube containing 710 l lysis buffer and loaded onto the instrument. An
internal control is added to each specimen by the use of working Panther Fusion Capture Reagent-S, and
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TABLE 1 Summary of limit-of-detection results

Molecular
assay
Xpert Xpress

No. of replicates detected at each dilution/total no. of replicates at indicated no. of copies/ml
(% positive rate)a

Final LoD
(no. of
copies/ml)b
100c

Gene
N2
E

20,000
1/1 (100)
1/1 (100)

10,000
N/A
N/A

5,000
N/A
N/A

2,000
10/10 (100)
10/10 (100)

1,000
9/9 (100)
9/9 (100)

500
9/10 (90)
10/10 (100)

100
7/10 (70)
10/10 (100)

50
4/8 (50)
7/8 (87.5)

5
0/5 (0)
0/5 (0)

ID NOW

RdRp

5/5 (100)

8/10 (80)

5/10 (50)

5/10 (50)

0/8 (0)

0/1 (0)

0/1 (0)

0/1 (0)

0/1 (0)

20,000

ePlex

N

10/10 (100)

N/A

N/A

10/10 (100)

9/9 (100)

7/10 (70)

1/10 (10)

1/4 (25)

0/4 (0)

1,000

aThe

limit of detection by positive rate for each gene target is highlighted in bold. N/A, not analyzed.
bThe ﬁnal LoD was based on each manufacturer’s results interpretation algorithm.
cAlso includes presumptive positive results.

hybridized nucleic acid is then separated using a magnetic ﬁeld. Following wash steps, 50 l of puriﬁed
RNA is eluted. Then, 5 l of eluted nucleic acid is transferred to a Panther Fusion reaction tube. The
Fusion SARS-CoV-2 assay ampliﬁes and detects two conserved regions of the ORF1ab gene in the same
ﬂuorescence channel, with ampliﬁcation of either or both regions leading to a production of a ﬂuorescent ROX signal. Reporting of a positive specimen requires only one of the two targets to be detected
(ORF1a or ORF1b gene).
Analytical sensitivity. Limit-of-detection (LoD) analyses were performed using an Exact Diagnostics
synthetic RNA quantiﬁed control (SARS-CoV-2 standard) containing ﬁve gene targets (E, N, ORF1ab, RdRP,
and S genes of SARS-CoV-2) (stock-keeping unit [SKU] COV019; Exact Diagnostics, Fort Worth, TX). A
starting concentration of 200,000 copies/ml control was used to prepare a serial dilution panel. The
control material was prepared using Ambion RNA storage solution (catalog no. AM7001; Thermo Fisher
Scientiﬁc) to limit the potential of degradation of the RNA transcript and aliquoted for testing to obtain
replicates at 20,000, 10,000, 5,000, 2,000, 1,000, 500, 100, 50, and 5 copies/ml (with numbers of replicates
ranging from 1 to 10, as shown in Table 1). The positive rate value was deﬁned as the lowest dilution at
which all replicates were positive at a 100% detection rate and was used to evaluate the analytical
sensitivity of all three sample-to-answer platforms.
Statistical methods. The reference standard was established as the result obtained from the Hologic
Panther Fusion SARS-CoV-2 assay. Percent positive agreement (PPA), percent negative agreement (NPA),
positivity rate, Kappa, and two-sided (upper/lower) 95% conﬁdence interval (CI) values were calculated
using Microsoft Ofﬁce Excel 365 MSO software (Microsoft, Redmond, WA). Cohen’s kappa values () were
calculated as a measure of overall agreement, with values categorized as representing almost perfect
results (values of ⬎0.90), strong results (0.80 to 0.90), moderate results (0.60 to 0.79), weak results (0.40
to 0.59), minimal results (0.21 to 0.39), or no results (0 to 0.20) (8, 9). The dose-response 95th percentile
(with 95% conﬁdence interval [CI]) model was assessed using Finney and Stevens calculations (10).

RESULTS
Analytical sensitivity. LoD was determined by preparing serial dilutions ranging
from 20,000 to 5 copies/ml using a known concentration of the Exact Diagnostics
SARS-CoV-2 control panel and was deﬁned as the minimum concentration with detection of 100% by positive rate. The LoD established by percent positive rate and the
manufacturer’s interpretation algorithm for each assay was determined to be 20,000
copies/ml for ID NOW, 1,000 copies/ml for ePlex, and 100 copies/ml for the Xpert Xpress
assay (including presumptive positive results) (Table 1).
Clinical performance. Clinical testing was performed on 108 retrospective and
prospective clinical specimens, and the results were compared to those obtained with
the reference standard. Xpert Xpress demonstrated a PPA of 98.3%, followed by ePlex
at 91.4% and ID NOW at 87.9%. NPA was also calculated and was 100% for each
platform evaluated (Table 2). One sample was invalid on ID NOW and was not included
in the calculations for this platform. Further evaluation of distributions of positive
results across all three platforms showed that Xpert Xpress detected a total of 57
positive results, followed by ePlex at 53 and ID NOW at 50. ePlex also detected 3
positive results that were not detected by ID NOW, and ID NOW detected 1 positive
result that was not detected by ePlex, but all 4 of those positive samples were detected
by Xpert Xpress, as well as 4 additional positive samples that were detected only by
Xpert Xpress. ePlex and ID NOW did not detect any additional results that were not
detected by Xpert Xpress. One specimen that was positive on Panther Fusion was not
detected on any of the 3 platforms.
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TABLE 2 Clinical performance comparison of three sample-to-answer EUA molecular
assays for the detection of SARS-CoV-2 (n ⫽ 108)
Reference standarda
Molecular assay
Xpert Xpress
Positive
Negative

Positive

Negative

Kappa ()
(ⴞ95% CI)b

PPA
(ⴞ95% CI)b

NPA
(ⴞ95% CI)b

57
1

0
50

0.98 (1–0.95)

98.3
(0.91–1)

100
(0.93–1)

ID NOWc
Positive
Negative

50
7

0
50

0.87 (0.96–0.78)

87.7
(0.76–0.95)

100
(0.93–1)

ePlex
Positive
Negative

53
5

0
50

0.91 (0.99–0.83)

91.4
(0.81–0.97)

100
(0.93–1)

aThe

reference standard was the Hologic Fusion assay. Data represent numbers of patients.
CI, upper/lower 95% conﬁdence interval (⬎0.90, almost perfect; 0.80 to 0.90, strong; 0.60 to 0.79,
moderate; 0.40 to 0.59, weak; 0.21 to 0.39, minimal; 0 to 0.20, none).
cID NOW had one invalid result that was removed from the analysis which was positive by the reference
standard and the other two methods.
b⫾95%

A total of eight discordant samples were found among the three sample-to-answer
platforms evaluated, with ID NOW having the most discordant results (n ⫽ 7), followed
by ePlex (n ⫽ 5) and Xpert Xpress (n ⫽ 1). All discordant results were negative results
compared to a positive result from the reference method. In evaluating the cycle
threshold (CT) values obtained by the reference method, A-24, which was the only
discordant specimen in detection by the Xpert Xpress assay, gave a CT value of 38.5,
which would be considered a positive specimen representing a low viral load. ePlex
exhibited negative results with specimens that had CT values ranging from 33.1 to 38.5,
while ID NOW exhibited negative results with specimens that had CT values that ranged
from 32 to 38.5 (Table 3).
Hands-on time (HoT), run time, and total turnaround time (TAT) per specimen were
evaluated. Xpert Xpress HoT is approximately 1 min per specimen, while ID NOW and
ePlex both had a HoT of approximately 2 min per specimen. ID NOW had the shortest
overall TAT of ⬃17 min for one specimen. The Xpert Xpress TAT was ⬃46 min for one
specimen and the ePlex TAT was ⬃1.5 h for one specimen, with the majority of the TAT
measured for each assay being assay run time. The ID NOW turnaround times can also
differ for positive specimens and can be as low as 5 min, including HoT (Table 4).
DISCUSSION
Clinical conﬁrmation of COVID-19 is at the core of our strategy to stop the current
spread of infection. It has recently been shown that SARS-CoV-2 has a basic reproduction number (R0) of 2.2, meaning that an infected person can spread the infection to
two additional persons on average (5, 6).

TABLE 3 Details of discordant samplesa
SARS-CoV-2 sample-to-answer molecular assay results
Sample ID
A-10
A-12
A-14
A-15
A-16
A-24
A-26
A-103
aDiscordant

Reference method
(CT value)
POS (33.1)
POS (33.2)
POS (34)
POS (32.6)
POS (33.2)
POS (38.5)
POS (36.2)
POS (32)

Xpert Xpress
(E/N2 CT values)
POS (32.8/35.8)
POS (31.7/34.6)
POS (33.3/35.5)
POS (32.2/35.4)
POS (33.6/36.4)
NEG (N/A)
POS (36.6/39.5)
POS (31.1/34.3)

ID NOW
POS
NEG
NEG
NEG
NEG
NEG
NEG
NEG

ePlex
NEG
NEG
NEG
POS
POS
NEG
NEG
POS

sample results are highlighted in bold. CT, cycle threshold; ID, identiﬁer; NEG, negative; POS,

positive.
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TABLE 4 Basic performance characteristics of three sample-to-answer EUA molecular SARS-CoV-2 assays evaluateda
Characteristic
Manufacturer
Sample type(s)

ID NOW COVID-19
Abbott
NPS, NS, TS

ePlex SARS-CoV-2
GenMark
NPS

Sample vol required (l)
Extraction required
Detection platform/system
Target region of SARS-CoV-2
Analytical sensitivity per claim

Xpert Xpress SARS-CoV-2
Cepheid
NPS, NS, midturbinate swab, nasal wash,
nasal aspirate
300
Yes (automated)
GeneXpert, Xpress, Inﬁnity
N2, E
250 copies/ml

200
No
ID NOW
RdRp
125 genome equivalents/ml

Maximum throughput
Hands-on time (per specimen)
Assay run time
User results interpretation
Overall turnaround time (per specimen)

4 per instrument (4-module conﬁguration)
⬃1 min
⬃45 min
No
⬃46 min

1 per instrument
⬃2 min
⬍15 min
No
⬃17 min

200
Yes (automated)
ePlex
N
100,000 RNA transcript
copies/ml
6 per tower
⬃2 min
⬃90 min
No
⬃1.5 h

aNPS,

nasopharyngeal swab; NS, nasal swab; TS, throat swab.

Vulnerable patient populations, such as people with preexisting medical conditions,
immunocompromised individuals, and the elderly, especially those living in a nursing
home or a long-term-care facility, are especially at risk (11, 12). With this in mind, it is
critical that patient results are as accurate as possible and are also available in a rapid
fashion to stop the spread of infection in real time.
We evaluated three sample-to-answer platforms currently in use in our health
system for the detection of SARS-CoV-2, including Xpert Xpress and ID NOW, which are
designed to be used in near-patient testing environments and outside the clinical
laboratory environment. LoD determination, correlation of clinical results, and performance comparisons, including HoT and overall TAT, were done for each assay as part
of our evaluation. This information is especially critical at the current moment, when
accurate and rapid results are at the center of clinical decision-making, both in
outpatient clinics and in the hospital. All three of these platforms are designed to
produce rapid test results, and each platform is a sample-to-answer system designed to
run one patient per test cartridge. This makes the comparison of these platforms
especially pertinent as decisions are made for testing in both the inpatient and
outpatient environments.
In our comparisons of all three platforms, Xpert Xpress outperformed both ID NOW
and ePlex, exhibiting the lowest LoD of all three platforms (100 copies/ml), whereas ID
NOW and ePlex had higher LoDs of 20,000 and 1,000 copies/ml, respectively (Table 1).
We also observed that in each case, the manufacturer’s stated LoD differed from our
ﬁndings, with ePlex having a much lower LoD than that stated in their EUA submission
(1,000 RNA copies/ml versus the EUA-listed value of 100,000 RNA transcript copies/ml),
while ID NOW had a much higher LoD than that stated in their EUA submission (20,000
RNA transcript copies/ml versus the EUA-listed value of 125 genome equivalents/ml).
The LoD reported by the manufacturer of Xpert Xpress was the closest to the measured
value among those reported by the manufacturers whose products were tested here
(100 RNA transcript copies/ml, including presumptive positives, versus the EUA-stated
250 copies/ml). This disparity might have been due to the use of different quantiﬁed
materials among the manufacturers. Our LoD ﬁndings also correlated with the clinical
sensitivities, which ranged from a high of 98.3% for Xpert Xpress to a low of 87.9% for
ID NOW, with ePlex falling in the middle at 91.4% (Table 2). A closer analysis of positive
results showed that whereas the majority of positives were detected by all three
platforms, Xpert Xpress detected four results that were missed by both ID NOW and
ePlex and also detected additional results singly detected by either ID NOW or ePlex.
All three assays had 100% speciﬁcity and did not exhibit false-positive results.
When it comes to the HoT and TAT of the three platforms, each platform has speciﬁc
advantages. Xpert Xpress is the easiest to use and requires the fewest technical
interventions, which include loading the sample and the cartridge. ID NOW has the
August 2020 Volume 58 Issue 8 e00783-20
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shortest sample-to-answer time at ⬃17 min maximum to ﬁnal result. ePlex has the
ability to test higher numbers of patients at once on a random-access 6-bay tower. Both
the Xpert Xpress and ePlex platforms can also be expanded by adding modules/bays
for more capacity in certain models of instrumentation, while ID NOW is limited to 1
sample testing port per instrument.
Some limitations of this study were that this was a single-center study and the
majority of specimens were initially tested on the ePlex system and were then stored
frozen. While this was the case, ePlex had performance sensitivity considerably lower
than that of the reference standard (Panther Fusion) and of Xpert Xpress and yet had
the competitive advantage as the assay that was initially performed on fresh specimens.
Considering this workﬂow limitation, the results of our study in regard to the sensitivity
of ePlex are even more telling, since the ePlex results do not contain testing after one
freeze-thaw of retrospective specimens, such as was the case for Xpert Xpress and ID
NOW (as well as the reference standard).
In addition, while the number of specimens included in the clinical correlation was
only 108, these specimens were chosen to span the positivity range of clinical specimens, including those specimens with a low viral load. Also, the percentage of positive
specimens in our study actually reﬂected the overall true positivity rate determined by
us (50% to 60% SARS-CoV-2 positive) for this time period.
In summary, we evaluated three sample-to-answer platforms for the detection of
SARS-CoV-2 using NP specimens, including two platforms that are designed to be used
in the near-patient testing environment, Xpert Xpress and ID NOW. Our results showed
that Xpert Xpress performed well and had the lowest LoD and highest sensitivity, while
ePlex and ID NOW had lower sensitivities and missed several positive patient specimens. The lack of sensitivity in both ID NOW and ePlex is particularly concerning in the
midst of this current pandemic, where identifying new infections is the bedrock of
limiting spread. While ID NOW is the most rapid of the three platforms tested, taking
⬃17 min from beginning to end to complete testing, it missed 12.3% of the positive
patients tested, exhibiting a sensitivity of 87.7% in our study. ePlex also missed 8.6% of
positive patients and had a sensitivity of 91.4% and also takes ⬃1.5 h to perform. In
contrast, Xpert Xpress missed 1.7% of positive patients, showing a sensitivity of 98.3%,
and takes ⬃46 min to perform. In conclusion, while ID NOW gives the most rapid result,
both ID NOW and ePlex (which takes substantially longer to produce results) lack
sensitivity compared to Xpert Xpress. These parameters will need to be considered
when deciding which testing platform should be implemented for COVID-19 testing.
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